Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlumosbartmab vs Denosumab for Bone Metastases from Breast Cancer
ChiCTR2600123763Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of narlumosbart in breast cancer, sponsored by Shanghai General Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
narlumosbart
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600123763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123763.